Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olpasiran - Amgen

Next Previous
Drug Profile

Olpasiran - Amgen

Alternative Names: AMG-890; ARC LPA; ARO LPA; RNAi ARC-LPA

Latest Information Update: 01 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arrowhead Pharmaceuticals
  • Developer Amgen
  • Class Cardiovascular therapies; Small interfering RNA
  • Mechanism of Action Lipoprotein A expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Cardiovascular disorders

Most Recent Events

  • 22 Aug 2025 Amgen initiates the phase III OCEAN(a)-PreEvent trial for Cardiovascular disorders in USA, Australia, Canada (SC, Injection) (NCT07136012)
  • 23 Jul 2025 Amgen initiates an expanded-access programme for Cardiovascular disorders (NCT07079267)
  • 04 Feb 2025 Amgen plans a phase-III trial for Cardiovascular disorders (In adults, In the elderly) in March 2026 (SC, Injection) (NCT07293260)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top